Apeiron RIA’s AbbVie ABBV Stock Holding History

Apeiron RIA’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-80,008	Closed	-$14.6M	–	206
2024 Q1	$14.6M	Sell	80,008 -5,572	-7%	-$960K	4.22%	3
2023 Q4	$13.3M	Hold	85,580	–	–	4.14%	4
2023 Q3	$12.8M	Hold	85,580	–	–	4.35%	3
2023 Q2	$11.5M	Hold	85,580	–	–	3.95%	3
2023 Q1	$13.8M	Hold	85,580	–	–	4.73%	2
2022 Q4	$13.8M	Sell	85,580 -1	-0%	-$153	5.29%	3
2022 Q3	$11.5M	Sell	85,581 -5,000	-6%	-$717K	5.29%	3
2022 Q2	$139K	Buy	90,581 +69	+0.1%	+$10.5K	38.75%	1
2022 Q1	$15.7M	Hold	90,512	–	–	7.48%	1
2021 Q4	$12.3M	Buy	+90,512	New	+$10.7M	5.03%	4

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Apeiron RIA's ABBV Position: Q2 2024 in Review

Apeiron RIA sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 80,008 shares — an estimated $14.6M sold.

Apeiron RIA first reported a position in ABBV in Q4 2021 and held it in 10 quarters. The position peaked at $15.7M in Q1 2022. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Apeiron RIA reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Apeiron RIA sold 80,008 AbbVie shares in Q2 2024, an estimated $14.6M.
Apeiron RIA first reported a position in AbbVie in Q4 2021 and held it in 10 quarters.
Apeiron RIA's AbbVie position peaked at $15.7M in Q1 2022.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Apeiron RIA's 13F filing for Q2 2024, filed 16 Jul 2024.